3 Regulatory Mistakes That Keep Coming Up in Biotech

After several recent conversations with biotech and digital health teams, a pattern keeps repeating.

Not around the science — that's usually strong.
It's around regulation.

1. "We'll think about it later"

Completely understandable.

The focus is on proving the biology, building something real, showing traction. Regulation feels like something for later.

But in practice, it affects:

Many teams end up doing a lot of work… and then realizing parts of it need to be redone.

2. A lot of data, but unclear what it actually shows

This comes up often.

There is usually a lot of data, but when asking:

…the answers are not always clear.

And that becomes very visible when speaking with pharma or investors.

3. Treating regulation as a checkbox

This is probably the biggest one.

Regulation is often treated as something to "get through" at the end.

But in reality, it shapes how others evaluate the opportunity:

If that part isn't clear, it affects how seriously the opportunity is taken.

What stronger teams tend to do differently

They don't overcomplicate it.

They simply think earlier about:

That alone makes a big difference.

At Precise X Med, we help biotech and digital health teams integrate regulatory thinking early — before it becomes an obstacle.